Ascletis Pharma, Inc. (1672) Stock Statistics & Valuation Metrics

Ascletis Pharma, Inc. has a market cap or net worth of HK$9.08B. The enterprise value is HK$6.76B.

Ascletis Pharma, Inc. has 998,958,560 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascletis Pharma, Inc.’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -14.94%.

The current PE Ratio of Ascletis Pharma, Inc. is ―. Ascletis Pharma, Inc.’s PEG ratio is -0.07.

In the last 12 months, Ascletis Pharma, Inc. had revenue of 1.28M and earned -300.94M in profits. Earnings per share was -0.30.

In the last 12 months, operating cash flow was -311.15M and capital expenditures -2.10M, giving a free cash flow of -313.25M billion.

Ascletis Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Ascletis Pharma, Inc. upcoming earnings date is Mar 31, 2026, TBA (Confirmed).

Ascletis Pharma, Inc. as a current ratio of 12.88, with Debt / Equity ratio of 0.23%

In the past 12 months, Ascletis Pharma, Inc. has paid 0.00 in taxes.

Ascletis Pharma, Inc. EV to EBITDA ratio is -5.05, with an EV/FCF ratio of -5.74.

Ascletis Pharma, Inc. has HK$1.80B in cash and marketable securities with HK$4.27M in debt, giving a net cash position of HK$1.80B billion.

Gross margin is 36.21%, with operating margin of -23025.64%, and net profit margin of -23455.65%.

The average price target for Ascletis Pharma, Inc. is HK$23.38, which is 11.43% higher than the current price. The consensus rating is Moderate Buy